...its board is evaluating all development, strategic or corporate opportunities available for onapristone, AR-42 and AR-12...
...completed a Phase I trial of AR-12 for advanced or recurrent solid tumors or lymphoma. AR-12...

...the North American Cystic Fibrosis meeting in Phoenix. AR-13 is an analog of the company’s AR-12...

...The European Commission granted Orphan Drug designation to AR-12 from Arno to treat cryptococcosis and tularemia...
...or recurrent solid tumors or lymphoma. Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Product: AR-12 (formerly OSU-03012...

...malignancies and in Phase I testing to treat solid tumors. Arno Therapeutics Inc. has AR-12 (OSU-03012...

...steps include identifying human melanomas that might respond to PDPK1 inhibitors. Arno Therapeutics Inc. has AR-12...

...and analyzing how PDPK1 is activated by pathogenic prions and amyloid peptides. Arno Therapeutics Inc.'s AR-12...

...steps could include testing clinical-stage PDK1 inhibitors in mouse models for PDAC. Arno Therapeutics Inc.'s AR-12...

...cancer models. Pfizer Inc. markets Rapamune rapamycin (sirolimus) to prevent organ rejection in renal transplantation. AR-12...

...Arno began an open-label, dose-escalation, U.S. and European Phase I trial to evaluate oral AR-12 given...
...days in up to 50 patients. Arno Therapeutics Inc. (OTCBB:ARNI), Fairfield, N.J. Product: AR-12 (formerly OSU-03012...

...and hematological cancers. In addition, the company hopes to submit INDs for preclinical oncology compounds AR-12...